These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16444966)

  • 1. [Primary chronic myelofibrosis in the Japanese population].
    Okamura T; Shimoda K
    Rinsho Ketsueki; 2005 May; 46(5):330-8. PubMed ID: 16444966
    [No Abstract]   [Full Text] [Related]  

  • 2. Myelofibrosis: biology and treatment options.
    Cervantes F
    Eur J Haematol Suppl; 2007 Oct; (68):13-7. PubMed ID: 17727559
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognosis and survivorship in primary myelofibrosis.
    Reilly JT
    Am J Hematol; 2010 Jan; 85(1):4-5. PubMed ID: 20029947
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical aspects of primary myelofibrosis in Japan].
    Shimoda K; Takenaka K; Kitanaka A; Akashi K
    Rinsho Ketsueki; 2014 Mar; 55(3):289-94. PubMed ID: 24681931
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pathophysiology of and therapy for primary myelofibrosis].
    Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1724-32. PubMed ID: 17802728
    [No Abstract]   [Full Text] [Related]  

  • 6. Myelofibrosis with myeloid metaplasia.
    Tefferi A
    N Engl J Med; 2000 Apr; 342(17):1255-65. PubMed ID: 10781623
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.
    Takenaka K; Shimoda K; Uchida N; Shimomura T; Nagafuji K; Kondo T; Shibayama H; Mori T; Usuki K; Azuma T; Tsutsumi Y; Tanaka J; Dairaku H; Matsuo K; Ozawa K; Kurokawa M; Arai S; Akashi K
    Int J Hematol; 2017 Jan; 105(1):59-69. PubMed ID: 27761702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT.
    Alchalby H; Lioznov M; Fritzsche-Friedland U; Badbaran A; Zabelina T; Bacher U; Stübig T; Ayuk FA; Zander AR; Kröger N
    Bone Marrow Transplant; 2012 Jan; 47(1):143-5. PubMed ID: 21358677
    [No Abstract]   [Full Text] [Related]  

  • 9. [Allogeneic hematopoietic cell transplantation for myelofibrosis: current status and future challenges].
    Takagi S
    Rinsho Ketsueki; 2022; 63(9):1252-1260. PubMed ID: 36198551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.
    Murata M; Suzuki R; Nishida T; Shirane S; Shimazu Y; Minami Y; Mori T; Doki N; Kanda Y; Uchida N; Tanaka M; Ishikawa J; Togitani K; Fukuda T; Ichinohe T; Atsuta Y; Nagamura-Inoue T; Kiyoi H
    Intern Med; 2020; 59(16):1947-1956. PubMed ID: 32801269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act.
    Tefferi A
    Bone Marrow Transplant; 2010 Mar; 45(3):419-21. PubMed ID: 20216545
    [No Abstract]   [Full Text] [Related]  

  • 12. Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant.
    Sora F; Giammarco S; Raiola AM; Di Grazia C; Bregante S; Gualandi F; Varaldo R; Chiusolo P; Sica S; Laurenti L; Innocenti I; Autore F; Metafuni E; Galli E; Bacigalupo A; Angelucci E
    Blood Cancer J; 2022 Jul; 12(7):111. PubMed ID: 35882842
    [No Abstract]   [Full Text] [Related]  

  • 13. Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis.
    Robin M; Espérou H; de Latour RP; Petropoulou AD; Xhaard A; Ribaud P; Socié G
    Br J Haematol; 2010 Sep; 150(6):721-4. PubMed ID: 20618333
    [No Abstract]   [Full Text] [Related]  

  • 14. Distinct profile of CD34
    Forte D; Barone M; Morsiani C; Simonetti G; Fabbri F; Bruno S; Bandini E; Sollazzo D; Collura S; Deregibus MC; Auteri G; Ottaviani E; Vianelli N; Camussi G; Franceschi C; Capri M; Palandri F; Cavo M; Catani L
    J Exp Clin Cancer Res; 2021 Feb; 40(1):49. PubMed ID: 33522952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [System mastocytosis: presentation of a case evolving into myelofibrosis and no response to interferon alfa 2b].
    de las Nieves M; Poveda F; Queipo de Llano MP; González-Hermoso C
    Sangre (Barc); 1997 Oct; 42(5):430-1. PubMed ID: 9424749
    [No Abstract]   [Full Text] [Related]  

  • 16. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines.
    Barosi G
    J Clin Oncol; 1999 Sep; 17(9):2954-70. PubMed ID: 10561375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis and management of idiopathic myelofibrosis.
    Reilly JT
    Baillieres Clin Haematol; 1998 Dec; 11(4):751-67. PubMed ID: 10640215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splenectomy and hemopoietic stem cell transplantation for myelofibrosis.
    Li Z; Gooley T; Applebaum FR; Deeg HJ
    Blood; 2001 Apr; 97(7):2180-1. PubMed ID: 11286221
    [No Abstract]   [Full Text] [Related]  

  • 19. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
    Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.
    Arora B; Ho CL; Hoyer JD; Mesa RA; Tefferi A
    Haematologica; 2004 Dec; 89(12):1454-8. PubMed ID: 15590395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.